Non-alcoholic fatty liver disease (NAFLD) is an umbrella term for a range of liver conditions affecting people who drink little to no alcohol. As the name implies, the main characteristic of NAFLD is too much fat stored in liver cells.
NAFLD is increasingly common around the world, especially in Western nations. In the United States, it is the most common form of chronic liver disease, affecting about one-quarter of the population.
Some individuals with NAFLD can develop nonalcoholic steatohepatitis (NASH), an aggressive form of fatty liver disease, which is marked by liver inflammation and may progress to advanced scarring (cirrhosis) and liver failure. This damage is similar to the damage caused by heavy alcohol use.
NAFLD usually causes no signs and symptoms. When it does, they may include:
Pain or discomfort in the upper right abdomen
NAFLD and NASH are both linked to the following:
Overweight or obesity
Insulin resistance, in which your cells don't take up sugar in response to the hormone insulin
High blood sugar (hyperglycemia), indicating pre-diabetes or type 2 diabetes
High levels of fats, particularly triglycerides, in the blood
Mayo Clinic: Click here to learn all about Fatty Liver Disease.
Do you suffer from Fatty Liver Disease? Then you may be eligible to participate in this Fatty Liver Disease clinical trial in San Diego. How to qualify for this Fatty Liver Disease clinical trial? Each clinical study has its own set of criteria. If you satisfy these criteria, you might qualify for this study. Here is a partial list of the criteria:
Are you between the ages of 18 and 75?
Have you been diagnosed with NASH as documented through liver biopsy performed no more than 6 months before randomization, defined according to NASH CRN criteria along with a NASH CRN fibrosis score between F2 and F3?
Hepatic steatosis on MRI (>= 8% average PDFF) prior to randomization
Other criteria may apply*
Learn More About This Trial